LOUISVILLE, Ky., April 10, 2024 (GLOBE NEWSWIRE) — BrightSpring Health Services (“BrightSpring” or “BrightSpring Health Services”) (NASDAQ: BTSG ) announced today that its Onco360®a leading independent oncology pharmacy, has been selected as a national pharmaceutical partner by Alexion Pharmaceuticals for its first-in-class oral factor D inhibitor, Voydeya® (Danicopan) to treat patients with a rare, life-threatening blood disorder called paroxysmal nocturnal hemoglobinuria (PNH) who suffer from extravascular hemolysis (EVH).
I entered® has been approved by the FDA as an add-on therapy to Ultomiris® (Ravulizumab) or Soliris® (Eculizumab) for patients living with PNH who experience persistent anemia or EVH. This innovative drug will complement current treatment regimens and help regulate the immune system, providing control and preventing the destruction of healthy blood cells.
“Although PNH is curable only with a bone marrow transplant, this innovative drug from Alexion is a significant advance in the treatment of PNH with EVH and will help improve the lives of those affected by this disease,” said BrightSpring’s President and CEO, John Russo. “We are extremely proud of Onco360® for being chosen as Voidea’s preferred pharmacy® as it demonstrates the company’s commitment to maintaining cutting-edge treatment options in the best possible way for patients living with cancer and complex diseases. We applaud their leadership in partnering with biopharma leaders to continually innovate the proven standard of care.”
“Onco360® is grateful and honored to partner with Alexion Pharmaceuticals to treat and support patients living with PNH with EVH and improve their quality of life,” said Benito Fernandez, Chief Commercial Officer at Onco360®. “This is another highly specialized, premium drug that will complement current treatment regimens, and we are proud to be a trusted pharmacy and implement leading clinical and service practices for this drug and patients.”
Onco360®works with the mission to improve the lives of patients battling cancer and living with other challenging and rare diseases. The pharmacy has robust access to limited-distribution oncology drugs and offers personalized services such as finding financial assistance, verifying insurance benefits, expert clinical counseling, physician, patient and family education and support, fast and accurate order processing and medication fulfillment, real-time digital and data support, hub services and 24/7 patient support.
To learn more about Onco360® and BrightSpring, please visit https://www.brightspringhealth.com/.
About BrightSpring Health Services
BrightSpring Health Services is the parent company of leading service lines that provide complementary and integrated home and community pharmacy and health care solutions for complex populations requiring specialty and/or chronic care. Through the company’s services, including pharmacy, primary care and home health, as well as rehabilitation and behavioral health, we provide comprehensive care and clinical solutions in all 50 states to more than 400,000 clients, customers and patients daily.
About Onco360 Oncology Pharmacy
Onco360 is one of the largest independent oncology pharmacy and clinical services companies in the country. Onco360 was founded in 2003 to bring together stakeholders involved in the cancer treatment process and serve the specialized needs of oncologists, patients, hospitals, oncology centers of excellence, manufacturers, health plans and payers. Distributes nationally through its network of oncology pharmacies accredited by URAC and ACHC. Headquartered in Louisville, Kentucky, Onco360 is the flagship specialty pharmacy brand of PharMerica Corporation, a leading institutional pharmacy, specialty infusion and hospital services company serving more than 350,000 healthcare and home care patients in the United States every day. For more information about Onco360, please visit onco360.com.
Media contact:
Lee White
[email protected]
502.630.7412
